A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
MD Anderson Study Status
Pembrolizumab, Paclitaxel, Carboplatin, Bevacizumab, Pemetrexed, Ipilimumab, Erlotinib, Gefitinib
The purpose of this study is to determine the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with unresectable or metastatic non-small cell lung cancer (NSCLC).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Non-small Cell Lung Carcinoma
Thoracic Head and Neck Medical
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.